Rajamani, Geetanjali;
Stafki, Seth A;
Daugherty, Audrey L;
Mantyh, William G;
Littel, Hannah R;
Bruels, Christine C;
Pacak, Christina A;
... Kang, Peter B; + view all
(2024)
Cognitive Decline and Other Late-Stage Neurologic Complications in Cockayne Syndrome.
Neurology: Clinical Practice
, 14
(4)
, Article e200309. 10.1212/CPJ.0000000000200309.
![[thumbnail of Giunti_mss cs late complications 09-10-2023.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Giunti_mss cs late complications 09-10-2023.pdf Access restricted to UCL open access staff until 17 May 2025. Download (423kB) |
Abstract
Background and Objectives: Cockayne syndrome (CS) is an ultra-rare, autosomal recessive, premature aging disorder characterized by impaired growth, neurodevelopmental delays, neurodegeneration, polyneuropathy, and other multiorgan system complications. The anatomic aspects of CS neurodegeneration have long been known from postmortem examinations and MRI studies, but the clinical features of this neurodegeneration are not well characterized, especially at later stages of the disease.// Methods: This was a retrospective observational study in which individuals with CS who survived beyond 18 years were ascertained at 3 centers in the United States, France, and the United Kingdom. Medical records were examined to determine the frequencies and features of the following neurologic complications: neurocognitive/neuropsychiatric decline (8 symptoms), tremors, neuropathy, seizures, and strokes.// Results: Among 18 individuals who met inclusion criteria, all but one (94.4%) experienced at least one symptom of neurocognitive/neuropsychiatric decline, with most individuals experiencing at least half of those symptoms. Most participants experienced tremors and peripheral neuropathy, with a few experiencing seizures and strokes. For individuals with available data, 100.0% were reported to have gait ataxia and neuroimaging showed that 85.7% had generalized cerebral atrophy on MRI while 78.6% had white matter changes.// Discussion: Symptoms of neurocognitive/neuropsychiatric decline are nearly universal in our cohort of adults with CS, suggesting that these individuals are at risk of developing neurocognitive/neuropsychiatric decline, with symptoms related to but not specific to dementia. Considering the prominent role of DNA repair defects in CS disease mechanisms and emerging evidence for increased DNA damage in neurodegenerative disease, impaired genome maintenance may be a shared pathway underlying multiple forms of neurocognitive/neuropsychiatric decline. Components of the DNA damage response mechanism may bear further study as potential therapeutic targets that could alleviate neurocognitive/neuropsychiatric symptoms in CS and other neurodegenerative disorders.
Archive Staff Only
 |
View Item |
